D-0096-2023 Class III Terminated
FDA drug recall D-0096-2023 was initiated by Jubilant Cadista Pharmaceuticals, Inc. on Dec 27, 2022 and is designated Class III. Reason for recall: Subpotent Drug: Out of specification for assay at the 18-month stability timepoint. The recall status is terminated (terminated Dec 5, 2023). Affected quantity: 14,061 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 11, 2023
- Initiation Date
- Dec 27, 2022
- Termination Date
- Dec 5, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 14,061 bottles
Product description
Prochlorperazine Maleate Tablets, USP 5mg, 100 tablets, RX Only, Jubilant Cadista Pharmaceuticals, Inc., Salisbury, Maryland 21801, NDC 59746-113-06
Reason for recall
Subpotent Drug: Out of specification for assay at the 18-month stability timepoint.
Distribution pattern
Nationwide in the USA.
Code information
Lot#: 21P0336, Exp: 04/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0096-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026